April 14, 2023

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important April 25 Deadline in Securities Class Action – CTLT

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and October 31, 2022, both dates inclusive (the “Class Period”), of the important April 25, 2023, lead plaintiff deadline.

SO WHAT: If you purchased Catalent securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Catalent class action, go to https://rosenlegal.com/submit-form/?case_id=12490 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles (“GAAP”); (2) the Company had material weaknesses in its internal control over financial reporting related to revenue recognition; (3) the Company falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (4) the Company disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company’s financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (5) as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company’s financial performance, outlook and regulatory compliance during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Catalent class action, go to https://rosenlegal.com/submit-form/?case_id=12490 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8807558

April 14, 2023

Centro Semillero Offers Two Master’s Programs and Endless Possibilities

Houston, Texas, April 13, 2023 (GLOBE NEWSWIRE) — You may have heard the motto, “Those who dare to teach must never cease to learn.” This principle strongly applies to two Houston-area educators who, through Centro Semillero at University of St. Thomas-Houston (UST), have confirmed their callings as teachers and fortified their faith. Moreover, they are applying the academic program’s four pillars — kindness, discipline, knowledge, and community — to everything they do.

Angel de Jesus Garcia, Current Master’s Student

One of them is Angel de Jesus Garcia, a college advisor at Houston Independent School District and currently enrolled in Centro Semillero’s Master of Sacred Scriptures Program.

“When my friends told me that St. Thomas was about to launch a master’s degree program in Spanish, I went to orientation and decided to give it try,” Garcia said. “That’s how I became part of the first generation of Spanish-speaking theology students, and I thank God for that decision.”

Garcia made this decision because it perfectly supported both his profession as an educator and his after-work role as a leader at his parish’s youth ministry where he attends pastoral meetings, plans retreats, and creates Christian formation programs.

About Centro Semillero

Centro Semillero was created in 2019 as a graduate studies program in pastoral and biblical studies theology at the UST School of Humanities. Offered online and 100% in Spanish, Centro Semillero offers two postgraduate programs: a Master’s in Pastoral Theology and a Master’s in Sacred Scriptures.

“Centro Semillero,” according to its director Father Dempsey Rosales Acosta, “is inspired by the book of Proverbs 2:2-3 when fulfilling the invitation to incline our hearts to the understanding and study of God to grow in his love. Our center offers the opportunity to fulfill this goal of personal and professional growth by obtaining a postgraduate degree in pastoral or biblical studies at UST from the comfort of your home with our 100% online programs.”

Iris Lai Nayas, MAPT ‘21

For Iris Lai Nayas, a 9th-grade Spanish teacher at Pasadena Independent School District, and a graduate of the Pastoral Theology program in 2021, the concepts she learned have opened a door for dialogue with colleagues from other religions.

Nayas said, “The program has helped me find pastoral strategies for interacting with my colleagues, who are not necessarily Catholic. The strategies enable me to dialogue with all of my colleagues and live experiences of faith without losing the essence of mine.”

Most importantly, the program has made her realize that through her interactions with her students and peers, she can be a testament to God’s presence.

“Today, schools they have taken God out of the classroom but thanks to this program, I understand that God has never been outside, and it is up to me to present him, through values, justice, love, prudence, prayer, and faith,” adds Nayas.

Thanks to her graduate degree, Nayas is also a facilitator in the Small Communities of Salt and Light of Maryknoll Fathers and Brothers.

How to Enroll

Centro Semillero has open enrollment for new students. To learn more about Centro Semillero click here.

Attachments

Sandra Soliz
University of St. Thomas - Houston
713-906-7912
solizs@stthom.edu

GlobeNewswire Distribution ID 8807777

April 14, 2023

Nyxoah Raises $3 Million from its At-the-Market Equity Offering

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Raises $3 Million from its At-the-Market Equity Offering

Mont-Saint-Guibert, Belgium – April 13, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company raised $3.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market (“ATM”) program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at the time of the sale. The proceeds will be used for general corporate purposes.

The ordinary shares described above were sold pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities and Exchange Commission (“SEC”) on December 22, 2022, which became effective on January 6, 2023, and a prospectus supplement dated January 6, 2023 and the accompanying prospectus the Company filed with the SEC in connection with the offer and sale of the Company’s common stock pursuant to the Controlled Equity Offering^SM Sales Agreement, dated as of December 22, 2022 with Cantor Fitzgerald & Co., as sales agent (prospectus@cantor.com).

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

ENGLISH_ATM_FINAL

GlobeNewswire Distribution ID 1000803834

April 14, 2023

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Alphabet Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – GOOG, GOOGL

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alphabet Inc. (NASDAQ: GOOG, GOOGL), the parent company of Google, between February 4, 2020 and January 23, 2023, both dates inclusive (the “Class Period”), of the important May 15, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Alphabet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Alphabet class action, go to https://rosenlegal.com/submit-form/?case_id=13312 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Alphabet used its dominance in the field of digital advertising to disadvantage website publishers and advertisers who used competing advertising products; (2) the foregoing conduct was anticompetitive in nature and likely to draw significant regulatory scrutiny; (3) Alphabet’s revenues were unsustainable to the extent that they were the product of said anticompetitive conduct; (4) Alphabet’s conduct, once revealed, would negatively impact the Company’s reputation and expose it to a heightened risk of litigation and regulatory enforcement action; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Alphabet class action, go to https://rosenlegal.com/submit-form/?case_id=13312 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

GlobeNewswire Distribution ID 8807550

April 14, 2023

Financial results of Lotte Chemicals Pakistan Limited for Quarter ended March 31, 2023

Karachi, Lotte Chemicals Pakistan Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Karachi on April 13, 2023.

The agenda of the meeting was discussion of profit and loss account for quarter ended March 31, 2023 which portrayed a profit of Rs. 2,542,357,000 with earnings per share 1.68 basic and diluted respectively.

Further, 20% payment of cash dividend, bonus shares and right shares was agreed.

Furthermore, the share transfer books of the company will remain closed from April 26, 2023 to April 28, 2023 (both days inclusive).

Lotte Chemical Pakistan Ltd is a supplier of purified terephthalic acid, an essential raw material used in the polyester industry. Lotte, the South Korean conglomerate, acquired the majority shareholdings in Pakistan PTA Limited (PPTA) in September 2009. Subsequently, the name of the Company was changed to Lotte Chemical Pakistan Ltd.

The plant at Port Qasim, Karachi was built in 1998. It produces Purified Terephthalic Acid (PTA), an essential raw material for Pakistan’s textile and PET packaging industries and forms the backbone of the polyester chain, including Polyester Staple Fibre, Filament Yarn and PET (bottle grade) resin.

The shares of the company are quoted on the Pakistan Stock Exchange Official Site with the total number of shares that are 1,514,207,200. The Earnings per share of the Company is 1.40 in 2020 which was 3.54 in 2019. Their Profit after tax was 2,125,105,000 in 2020 which was 5,360,370,000 in 2019.

April 14, 2023

Board of directors meeting Rescheduled of Habib Metropolitan Bank Limited

Karachi, Habib Metropolitan Bank Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on April 19, 2023 at Karachi. The agenda of the meeting will to consider the Quarterly Accounts for the period ended March 31, 2023 for declaration of any entitlement has been rescheduled on April 19, 2023.

Further, the company has declared the closed period from April 12, 2023 to April 19, 2023.

Habib Metropolitan Bank Limited was incorporated in Pakistan on 3 August 1992, as a public limited company and is engaged in commercial banking and related services. The Bank is a subsidiary of Habib Bank AG Zurich - Switzerland (the holding company with 51% shares in the Bank) which is incorporated in Switzerland.

Habib Metro Bank commenced its commercial-banking operations as Metropolitan Bank in October 1992 when the Bank merged with Habib Bank AG Zurich’s Pakistan operations. The merged entity was named Habib Metropolitan Bank Limited.

Habib Metro Bank currently operates with nationwide network of over 400 branches in more than 138 cities across Pakistan. Habib Metro offers retail, commercial, consumer and corporate banking solutions to its clientele, in addition to its expertise of trade finance. The Bank also of provides highly innovative e-Banking and Shariah-compliant Islamic Banking solutions.

The total numbers of shares of the Company are 1,047,831,480. The Earnings per share of the Company is 11.46 in 2020 which was 6.28 in 2019. Their Profit after Taxation is 12,008,196,000 in 2020 which was 6,583,481,000 in 2019.

April 14, 2023

Change of Resignation of Directors of Lotte Chemicals Pakistan Limited

Karachi, Lotte Chemicals Pakistan Limited informed Pakistan Stock Exchange that Mr. Adnan Afridi has ceased to be the Director of the Company with effect from April 14, 2023.